AstraZeneca’s Menelas Pangalos: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
With AstraZeneca in the midst of a major R&D overhaul, Menelas Pangalos, the company’s head of discovery research and early-stage development in small molecules, talked to “The Pink Sheet” DAILY about how the new R&D structure will improve the big pharma’s research productivity.
You may also be interested in...
AstraZeneca: New HQ And R&D Site Underscore Its U.K. Commitment
Design plans for AstraZeneca’s new, purpose-built global headquarters and R&D center being constructed in the university town Cambridge underscore the pure pharma’s commitment to innovative science as a standalone, U.K.-based company, says head of early development Menelas Panaglos.
No Surprise AstraZeneca Singles Out Emerging Markets For Growth, But Japan Too?
Japan offers AstraZeneca a patent expiry cushion as the company tries to right itself elsewhere.
AstraZeneca’s R&D Restructuring Follows Hot Spot Trend
In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.